Dupilumab

(Dupixent®)

Dupilumab

Drug updated on 11/13/2023

Dosage FormInjection (subcutaneous: 100 mg/ 0.67 mL, 200 mg/1.14 mL, 300 mg/2 mL)
Drug ClassInterleukin-4 receptor alpha antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • Indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
  • Indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
  • Indicated for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE).
  • For the treatment of adult patients with prurigo nodularis (PN)

Product Monograph / Prescribing Information

Document TitleYearSource
Dupixent (Dupilumab) Prescribing Information.2022Regeneron Pharmaceuticals, Tarrytown, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Dupilumab in Inflammatory Skin Diseases: A Systematic Review.2023Biomolecules
Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors. 2022Journal of the European Academy of Dermatology and Venereology
Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. 2022Journal of Medical Economics
Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis.2022Cells
Facial and neck erythema associated with dupilumab treatment: a systematic review. 2021Journal of the American Academy of Dermatology
Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines.2021Allergy
Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. 2021Allergy
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. 2021Allergy
Biological therapies for atopic dermatitis: a systematic review. 2021Dermatology
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. 2021Journal of the European Academy of Dermatology and Venereology
Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. 2021JAMA Dermatology
Clinical and pharmacoeconomic combined report: dupilumab (Duxipent) for type 2 or eosinophilic asthma. 2021CADTH
Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma.2021Cochrane Database of Systematic Review
Effects of systemic therapies on pruritus in adults with atopic dermatitis: a systematic review and meta-analysis.2021Clinical and Experimental Dermatology
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis. 2021Rhinitis, Sinusitis, and Ocular Allergy
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis.2021Rhinitis, Sinusitis, and Ocular Allergy
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis.2021Journal of the European Academy of Dermatology and Venereology
Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis.2021Expert Review of Clinical Pharmacology
Comparative efficacy and safety of dupilumab and benralizumab in patients with inadequately controlled asthma: a systematic review. 2020International Journal of Molecular Sciences
The role of biologics in chronic rhinosinusitis: a systematic review. 2020International Forum of Allergy and Rhinology
Clinical review report: dupilumab (Dupixent) for patients aged 12 years and older with moderate-to-severe atopic dermatitis.2020CADTH
Biologics for chronic rhinosinusitis.2020The Cochrane Database of Systematic Reviews
Systemic treatments for eczema: a network meta‐analysis.2020The Cochrane Database of Systematic Reviews
Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.2020Current Medical Research and Opinion
Use of dupilumab on the treatment of moderate-to-severe asthma: a systematic review. 2019Revista da Associação Médica Brasileira
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. 2019Respiratory Research
Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. 2019The Journal of Asthma
Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis.2018American Journal of Clinical Dermatology
Clinical review report: dupilumab (Dupixent) for adult patients with moderate-to-severe atopic dermatitis. 2018CADTH
Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. 2018Journal of Dermatological Science

Clinical Practice Guidelines